![BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine](https://www.science.org/cms/asset/aff01e29-3536-466a-9bbc-a839e7e344f4/aax2625-f1.gif)
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
![Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo - QIMA Life Sciences Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo - QIMA Life Sciences](https://qima-lifesciences.com/wp-content/uploads/2020/06/mw_Type-1-cytokines.jpg)
Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo - QIMA Life Sciences
Caractérisation des altérations du microbiote respiratoire et investigation des sous-populations de macrophages impliquées da
![HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast | Journal of Hematology & Oncology | Full Text HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-021-01158-3/MediaObjects/13045_2021_1158_Fig1_HTML.png)
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast | Journal of Hematology & Oncology | Full Text
Salomon Anne - avis, photos, numéro de téléphone et adresse - Hôpitaux vétérinaires à Grand Est - Nicelocal.fr
![Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression - QIMA Life Sciences Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression - QIMA Life Sciences](https://qima-lifesciences.com/wp-content/uploads/2019/09/mw_Oncostatin-M-2019.png)
Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression - QIMA Life Sciences
![BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC](https://europepmc.org/articles/PMC8662740/bin/nihms-1731291-f0002.jpg)
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC
![Bérengère OUINE | Institut Curie, Paris | Département de Recherche Translationnelle | Research profile Bérengère OUINE | Institut Curie, Paris | Département de Recherche Translationnelle | Research profile](https://i1.rgstatic.net/ii/profile.image/439327147728897-1481755162733_Q512/Berengere-Ouine.jpg)